{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:03:46Z","timestamp":1789657426151,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate changes in biological therapy persistence for ulcerative colitis during Japan's first COVID\u201019 state of emergency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a nationwide health insurance claims database, we identified patients with ulcerative colitis who received biological maintenance therapy between January 2014 and December 2022. Interrupted time series analysis was used to evaluate immediate level changes and post\u2010intervention changes in trends in treatment non\u2010persistence after the state of emergency. Kaplan\u2013Meier analysis compared time to non\u2010persistence between patients initiating biological therapy in the pre\u2010 and post\u2010intervention periods using log\u2010rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1197 eligible patients (67.1% male; median age, 40.0\u2009years [interquartile range, 29.0\u201350.0\u2009years]), 384 received infliximab; 375, adalimumab; 286, vedolizumab; and 152, golimumab. Interrupted time series analysis showed no clear evidence of an immediate level change in treatment non\u2010persistence after intervention (level change, 0.38;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.822) or a post\u2010intervention change in trend (change in trend, \u22120.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.167). Kaplan\u2013Meier analysis showed no significant difference in time to non\u2010persistence between pre\u2010 and post\u2010intervention initiators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biological therapy persistence for ulcerative colitis was largely maintained during the COVID\u201019 pandemic in Japan. These findings suggest that the pandemic was not associated with a marked change in treatment persistence in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70377","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:53:42Z","timestamp":1776380022000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>COVID<\/scp>\n                    \u201019 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database"],"prefix":"10.1002","volume":"35","author":[{"given":"Mitsuhiro","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko M.","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"},{"name":"Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"},{"name":"Department of Gastroenterology and Hepatology Kumamoto University Hospital  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-9427","authenticated-orcid":false,"given":"Satomi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"},{"name":"Department of Clinical Medicine, Institute of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.9397"},{"key":"e_1_2_14_8_1","unstructured":"[COVID\u201019] Declaration of a State of Emergency in Response to the Novel Coronavirus Disease Prime Minister's Office of JapanApril 7 2020. Accessed March 28 2025 https:\/\/japan.kantei.go.jp\/ongoingtopics\/_00018.html."},{"key":"e_1_2_14_9_1","unstructured":"[COVID\u201019] Declaration of a State of Emergency in Response to the Novel Coronavirus Disease Prime Minister\u2019s Office of JapanApril 16 2020. Accessed April 11 2025 https:\/\/japan.kantei.go.jp\/ongoingtopics\/_00020.html."},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010022\u201007422\u20107"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo\u20102020\u2010000786"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620929133"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.02.044"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.032"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2022.9264\/2022"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.044"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010020\u201006807\u20100"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.422"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2012.04167.x"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz001"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010024\u201001274\u20101"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252468"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010022\u201001949\u20106"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1978205"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:06:14Z","timestamp":1789653974000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/pds.70377"],"URL":"https:\/\/doi.org\/10.1002\/pds.70377","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70377"}}